Aquestive Therapeutics, Inc. Cost of Revenue
Aquestive Therapeutics, Inc. (AQST) reported Cost of Revenue of $4.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-11
- Aquestive Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $4.02M, a 11.93% decline year-over-year.
- Aquestive Therapeutics, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $3.47M, a 5.01% decline year-over-year.
- Aquestive Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $5.84M, a 29.12% increase year-over-year.
- Aquestive Therapeutics, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $4.51M, a 1.56% increase year-over-year.
- Aquestive Therapeutics, Inc. cost of goods and services sold for fiscal 2025 was $18.55M, a 3.82% increase from fiscal 2024.
- Aquestive Therapeutics, Inc. cost of goods and services sold for fiscal 2024 was $17.87M, a 14.20% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. cost of goods and services sold for fiscal 2023 was $20.83M, a 7.45% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. cost of goods and services sold for fiscal 2022 was $19.39M.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $4.02M 10-Q · filed 2026-08-11 | $7.49M 10-Q · filed 2026-08-11 | $13.32M derived: sum of 3 quarters · filed 2026-08-11 | $17.83M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $3.47M 10-Q · filed 2026-05-13 | $9.30M derived: sum of 2 quarters · filed 2026-05-13 | $13.81M derived: sum of 3 quarters · filed 2026-05-13 | $18.37M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $5.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $10.34M derived: sum of 2 quarters · filed 2026-03-04 | $14.90M derived: sum of 3 quarters · filed 2026-08-11 | $18.55M 10-K · filed 2026-03-04 |
| 2025-09-30 | $4.51M 10-Q · filed 2025-11-05 | $9.07M derived: sum of 2 quarters · filed 2026-08-11 | $12.72M 10-Q · filed 2025-11-05 | $17.24M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $4.56M 10-Q · filed 2026-08-11 | $8.21M 10-Q · filed 2026-08-11 | $12.73M derived: sum of 3 quarters · filed 2026-08-11 | $17.17M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $3.65M 10-Q · filed 2026-05-13 | $8.17M derived: sum of 2 quarters · filed 2026-05-13 | $12.61M derived: sum of 3 quarters · filed 2026-05-13 | $17.14M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $8.96M derived: sum of 2 quarters · filed 2026-03-04 | $13.48M derived: sum of 3 quarters · filed 2026-03-04 | $17.87M 10-K · filed 2026-03-04 |
| 2024-09-30 | $4.44M 10-Q · filed 2025-11-05 | $8.96M derived: sum of 2 quarters · filed 2025-11-05 | $13.35M 10-Q · filed 2025-11-05 | $18.03M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $4.53M 10-Q · filed 2025-08-11 | $8.91M 10-Q · filed 2025-08-11 | $13.59M derived: sum of 3 quarters · filed 2025-08-11 | $18.39M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $4.39M 10-Q · filed 2025-05-12 | $9.07M derived: sum of 2 quarters · filed 2025-05-12 | $13.87M derived: sum of 3 quarters · filed 2025-05-12 | $20.48M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $4.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $9.48M derived: sum of 2 quarters · filed 2025-03-05 | $16.09M derived: sum of 3 quarters · filed 2025-03-05 | $20.83M 10-K · filed 2025-03-05 |
| 2023-09-30 | $4.80M 10-Q · filed 2024-11-04 | $11.41M derived: sum of 2 quarters · filed 2024-11-04 | $16.15M 10-Q · filed 2024-11-04 | $21.46M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $6.62M 10-Q · filed 2024-08-06 | $11.35M 10-Q · filed 2024-08-06 | $16.66M derived: sum of 3 quarters · filed 2024-08-06 | $21.28M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $4.74M 10-Q · filed 2024-05-07 | $10.04M derived: sum of 2 quarters · filed 2024-05-07 | $14.67M derived: sum of 3 quarters · filed 2024-05-07 | $19.91M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $9.93M derived: sum of 2 quarters · filed 2024-03-05 | $15.17M derived: sum of 3 quarters · filed 2024-03-05 | $19.39M 10-K · filed 2024-03-05 |
| 2022-09-30 | $4.63M 10-Q · filed 2023-11-06 | $9.87M derived: sum of 2 quarters · filed 2023-11-06 | $14.08M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | $5.24M 10-Q · filed 2023-08-07 | $9.46M 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $4.21M 10-Q · filed 2023-05-02 | |||
| 2021-09-30 | $4.40M 10-Q · filed 2022-11-01 | $8.87M derived: sum of 2 quarters · filed 2022-11-01 | $11.62M 10-Q · filed 2022-11-01 | $14.41M derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $4.47M 10-Q · filed 2022-08-02 | $7.22M 10-Q · filed 2022-08-02 | $10.01M derived: sum of 3 quarters · filed 2022-08-02 | $12.99M derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | $2.76M 10-Q · filed 2022-05-04 | $5.54M derived: sum of 2 quarters · filed 2022-05-04 | $8.52M derived: sum of 3 quarters · filed 2022-05-04 | $12.06M derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | $2.79M 10-K · filed 2021-03-09 | $5.77M derived: sum of 2 quarters · filed 2021-11-02 | $9.30M derived: sum of 3 quarters · filed 2021-11-02 | $12.96M 10-K · filed 2021-03-09 |
| 2020-09-30 | $2.98M 10-Q · filed 2021-11-02 | $6.52M derived: sum of 2 quarters · filed 2021-11-02 | $10.18M 10-Q · filed 2021-11-02 | $16.97M derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | $3.54M 10-Q · filed 2021-08-03 | $7.20M 10-Q · filed 2021-08-03 | $13.99M derived: sum of 3 quarters · filed 2021-08-03 | $18.63M derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $3.66M 10-Q · filed 2021-05-04 | $10.45M derived: sum of 2 quarters · filed 2021-05-04 | $15.09M derived: sum of 3 quarters · filed 2021-05-04 | $20.51M derived: sum of 4 quarters · filed 2021-05-04 |
| 2019-12-31 | $6.79M 10-K · filed 2021-03-09 | $11.44M derived: sum of 2 quarters · filed 2021-03-09 | $16.86M derived: sum of 3 quarters · filed 2021-03-09 | $20.36M 10-K · filed 2021-03-09 |
| 2019-09-30 | $4.64M 10-K · filed 2021-03-09 | $10.06M derived: sum of 2 quarters · filed 2021-03-09 | $13.57M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | $5.42M 10-K · filed 2021-03-09 | $8.93M 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $3.51M 10-K · filed 2021-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |